STADA Arzneimittel AG — Earnings Release 2002

Aug 26, 2002

News Details

Ad-hoc | 26 August 2002 11:25

STADA Arzneimittel AG english

STADA: Half-year results confirm raised forecast Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– STADA: Half-year results confirm raised forecast In the first half of 2002, STADA increased consolidated sales by +15% to EUR 309.2m. Its three core businesses generics, brands and special pharmaceuticals grew by +28% to EUR 266.5m. The non-core commercial business was reduced, as planned, by -31% to EUR 40.4m, mainly as a result of the restructuring of the Dutch commercial business operationally completed on June 30. Organic growth in the core segments amounted to +17%. Acquisitions accounted for 11 percentage points of the sales growth in the core segments. The results confirm the forecast for the year 2002, which was raised at the end of June (sales growth for the group clearly in the double digit percentage range, at least +25% growth for the core segments). All key earnings figures for the first six months, reported in 2002 for the first time using IAS, are clearly higher than those of the previous year. That applies not only to the statutory retroactively adjusted IAS results for 2001. Also compared to last years semi-annual results, reported using HGB, all key earnings figures were significantly higher than those of the previous year, despite the fact that due to the special effects published earlier (1995-1998 tax audit, sale of company shares), the 2001 HGB figures provide a distinctly higher starting point (2001 result after tax under HGB, EUR 24.7 million and according to the corresponding IAS result EUR 13.1 million). In the first half of 2002, the STADA group reported EBITDA of EUR 51.8m (+52% IAS vs. +38% HGB), EBT of EUR 33.0m (+39% IAS vs. +25% HGB), consolidated net income of EUR 19.8m (+93% IAS vs. +55% HGB), and EPS of EUR 1.06 (up +83% IAS vs. +45% HGB/DVFA). These encouraging results confirm STADAs increased earnings forecast of consolidated earnings before taxes of at least EUR 60m for 2002 as a whole. Full details (half-year report, slide presentation) are available at http://www.stada.de For further information please contact: STADA Arzneimittel AG / Corporate Communications / D-61118 Bad Vilbel Phone: +49(0) 6101 603-113 / Fax: +49(0) 6101 603-506 / E-mail: communication@stada.de. end of ad-hoc-announcement (c)DGAP 26.08.2002 ——————————————————————————– WKN: 725180; ISIN: DE0007251803; Index: MDAX Listed: Amtlicher Markt in Frankfurt und Düsseldorf; Freiverkehr in Berlin, Bremen, Hamburg, München und Stuttgart 261026 Aug 02